86
Kronik Hepatit B
2010;51:422–430.
39.
Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B
virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of
therapy. Hepatology 2009;49:1503–1514.
40.
Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-
refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039–
2049.
41.
Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine
treatment for chronic hepatitis B. Hepatology 2002; 36:186–194.
42.
Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir
disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B.
Gastroenterology 2012; 143:619–628, e611.
43.
Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior
to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486–
495.
44.
Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment
of chronic hepatitis B with entecavir in patients with impaired liver function.
Hepatology 2009;50:2001–2006.
45.
Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir
dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Hepatology 2008; 48:750–758
46.
Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF),
emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis
B liver disease. Hepatology 2011;53:62–72.
47.
Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir
versus adefovir in chronic hepatitis B patients with hepatic decompensation: a
randomized, open-label study. Hepatology 2011;54:91–100.
48.
Baykam N, Tütüncü E, Güner R, Yamazhan T, Hızel K, Kandemir O, İnan D. Kronik
Hepatit B de Tenofovir Tedavisinin Etkinliği ve Güvenilirliği: Dördüncü yıl Gerçek
Yaşam Verileri. Viral Hepatit Kongresi. 25-28 Mart 2014. Antalya
49.
Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce
temporary hepatitis B e antigen seroconversion in most patients with chronic
hepatitis B. Gastroenterology 2010; 139:491–498.
50.
Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response
to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using
on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251–1257.
51.
Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil
fumarate detected after up to 144 weeks of therapy in patients monoinfected with
chronic hepatitis B virus. Hepatology 2011;53:763–773.
